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CASE REPORT
Intravenous Immunoglobulin Treatment in a Child with 
Resistant Atopic Dermatitis
Hyuck Hoon Kwon, M.D., Kyu Han Kim, M.D., Ph.D.
Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
In a subgroup of patients suffering from atopic dermatitis 
(AD), treatment is quite difficult even after taking oral 
immunosuppressants. High-dose intravenous immunoglo-
bulin (IVIG) treatment has been reported to be beneficial for 
them in a few uncontrolled trials. Herein we report a case of 
intractable AD in a 5-year-old girl who had significant 
clinical improvement after receiving 3 cycles of IVIG 
treatment (2 g/kg) without notable side effects. Since the first 
infusion of IVIG, the patient’s skin lesions improved steadily 
and the improvement persisted until the 8-month follow-up. 
The eczema area and severity index score decreased 
remarkably, while immunologic parameters did not cor-
relate with clinical improvement. This case suggests that 
IVIG therapy can be quite effective and safe for children with 
resistant AD. (Ann Dermatol 24(1) 66∼69, 2012)
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INTRODUCTION
Atopic dermatitis (AD) is one of the most common derma-
tologic diseases, affecting approximately 20% of children 
living in industrialized countries. Moreover, approxima-
tely 70% of cases of AD affect children less than 5 years of 
age
1,2. Most cases of AD are effectively treated with 
topical steroids, topical calcineurin inhibitors and inter-
mittent use of immunosuppressive agents, including oral 
corticosteroids and cyclosporine. However, for recalci-
trant AD, continuous use of systemic immunosuppressive 
agents is used but is limited by the adverse effects, es-
pecially for children. For this subgroup of patients, a num-
ber of clinical trials based on immunomodulatory drugs 
have been conducted with limited success
3-5, and high- 
dose intravenous immunoglobulin (IVIG) therapy has 
been reported to be effective in some recent trials
6-12; in 
particular, children have shown much higher responses 
than adults
6-8, and no serious side effects accompanied the 
therapy. In the current report, we present the case of a 
5-year-old female with treatment-refractory AD who was 
remarkably improved with IVIG therapy without notable 
side effects. Her state of remission continued for 8 months 
without disease recurrence.
CASE REPORT
A 5-year-old female with a 3-year history of treatment- 
refractory AD was referred to our Pediatric Dermatology 
Clinic. She had failed to respond to 2 years of topical 
steroids and calcineurin inhibitors. Oral steroid treatments 
as an inpatient and outpatient during the last year were 
not much help. Recurrent staphylococcal infections and 
severe pruritus resulted in numerous hospital admissions. 
She was clinically depressed and needed a psychiatric 
consultation. She didn’t show any symptoms of allergic 
rhinitis and asthma. There was also no family history of 
AD, allergic rhinitis and asthma. Quantitative measure-
ment of the extent and severity of the AD was made using 
an eczema area and severity index (EASI) scoring system, 
the initial value of which was 30 (Fig. 1A). Laboratory 
results showed a total IgE of 11,000 kU/L and multiple 
allergen stimultaneous tests (RIDA
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Fig. 1. Significant improvement of 
atopic dermatitis after intravenous 
immunoglobulin (IVIG) therapy. (A)
Before IVIG treatment. (B) Three 
months follow up after 3 cycles of
IVIG treatment (2 g/kg).
Fig. 2. Patient skin scores measured using the EASI score are
shown as solid lines. It can be seen that the score decreased 
steadily during a full course of IVIG theray. EASI: eczema area
and severity index, IVIG: intravenous immunoglobulin.
System, R-Biopharn, Darmstadt, Germany) were positive 
for D. farinae (grade 5), Alternaria (grade 4), house dust 
(grade 3), and cat (grade 3). The percentage of blood 
eosinophils was 15.2. She was first treated with 
cyclosporine (5 mg/kg) without significant benefits; the 
drug was discontinued after 3 months. After stopping 
cyclosporine treatment, the patient’s state was slightly 
aggravated for 7 weeks. The EASI score was 32, which 
was its highest during the whole disease course. Then, 
IV-GLOBULIN (Greencross, Yongin, Korea) monotherapy 
was administered (2 g/kg monthly over 5 days) after 
hospital admission. Although she experienced mild 
nausea and headaches with every infusion, the skin 
symptoms subsided as the rate of infusion was decreased 
and oral antihistamines were administered. After 3 cycles 
of treatment with IVIG, the skin lesions improved 
dramatically (Fig. 1B) and the EASI score declined from 32 
to 4 (Fig. 2). The total IgE level and blood eosinophil 
percentage were 9,000 kU/L and 15.3% each, which did 
not change significantly during clinical improvement. 
After 8 months of follow up in the outpatient clinic, the 
patient’s AD remained in a state of remission; at that time 
she was taking a mild topical steroid and using an 
emollient.
DISCUSSION
IVIG has expanded beyond its traditional role as a 
treatment for primary immunodeficiencies, and is widely 
used in treating severe dermatologic diseases. IVIG has 
been increasingly used for dermatologic indications, in-
cluding dermatomyositis, autoimmune bullous disorders, 
vasculitic syndromes, and toxic epidermal necrosis; the 
European Union guidelines have recently been suggested
13. 
In addition to the above-mentioned indications, the high 
value of IVIG therapy in dermatologic diseases that are 
otherwise recalcitrant to conventional treatment is being 
consistently reported.
Regarding the clinical use of IVIG for AD, double-blind, 
placebo-controlled studies have not been conducted. One 
randomized study
14 involving 9 adult patients with AD 
treated with a single cycle of IVIG monotherapy did not 
show significant clinical improvement. However, in 
several case reports and uncontrolled trials, the clinical 
efficacy of IVIG for children, have been consistently re-
ported
6-12. There have been 4 open trials of immuno-
globulin treatment involving children with severe AD. 
Kimata
6 administered IVIG (0.4 g/kg) to 4 AD patients, 2 
of whom had underlying Kawasaki disease and the others 
had idiopathic thrombocytopenic purpura. All of the 
children improved in 4∼7 days with sustained remission 
for 6 months. With clinical improvement, the serum IgE 
level and eosinophil count also decreased. Huang et al.
7 
reported that 5 children with severe AD and no other 
underlying diseases received 3 cycles of IVIG (2 g/kg), and HH Kwon and KH Kim
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all had marked improvement. The remission persisted 
over 6 months without relapse. Other immunologic mar-
kers, including ICAM-1, ELAM-1, ECP, and IL-2R de-
creased accordingly. Noh and Lee
8 reported that patients 
with recalcitrant AD showed clinical improvement to 
variable degrees after receiving a single cycle of relatively 
low-dose IVIG (patients weighing ＜30 kg were treated 
with 500 mg/kg of IVIG and those weighing ＞30 kg were 
treated with 15 g of IVIG) over a 3-week follow-up period. 
The only case which did not show clinical improvement 
after receiving IVIG (1 g/kg) was an 8-month-old boy with 
Wiskott-Aldrich syndrome
9.
In our case, the patient received 3 cycles of IVIG (2 g/kg) 
and had dramatic clinical improvement without recur-
rence for 8 months and without notable side effects. Our 
treatment regimen was similar to that in the study of 
Huang et al.
7, while the immunologic parameters did not 
change significantly before and after IVIG treatments. 
Comparing with previous trials, our patient showed a 
more pronounced clinical response and maintained a 
longer prolonged remission state. Although the specific 
dosage regimens and follow-up periods were different in 
the above trials and our case, we can draw the following 
conclusions tentatively: 1) a few cycles of IVIG mono-
therapy is clinically effective in pediatric patients with 
refractory AD, with an early clinical response and prol-
onged remission; 2) no significant side effects were ob-
served in the trials; 3) immunologic parameters reflected 
clinical improvement in some cases. While both reporting 
bias for successful outcomes and the small number of total 
patients in clinical trials should be taken into account 
carefully, IVIG monotherapy is considered especially 
useful for children with severe AD. This could be expl-
ained by the fact that the immunoregulatory function of 
IVIG is more profound in the relatively immature immune 
system of children, although further research is required 
for confirmation.
Compared with other immunosuppressants for recalcitrant 
AD, the safety profile of IVIG appears to be outstanding. 
Most of the reported side effects are mild and self- 
limiting
15 including headache, low grade fever, nausea, 
vomiting and flushing. Side effects of IVIG vary from 
individual-to-individual and often occur 30∼60 min after 
the onset of the infusion. These side effects are usually 
overcome by reducing the infusion rate and administering 
antihistamines or non-steroidal anti-inflammatory drugs 
before beginning the infusion. In our case, the patient had 
headaches, nausea, and fevers immediately after the start 
of all three infusions, which resolved after slowing the 
infusion rate and taking oral antihistamines. In very rare 
cases, severe side effects, such as aseptic meningitis, 
stroke, and anaphylactic shock, might occur during the 
infusion, especially for patients with underlying risk fac-
tors. Therefore, performing a medical work-up is impor-
tant and adverse effects can be minimized by following 
the guidelines in the physician’s checklist
16. About po-
ssible mechanisms of IVIG treatment, modulation of T 
helper 1 (Th1) and Th2 cytokine production is suggested 
as one of the possible mechanisms. Intracellular IL-4 
decreases after infusing high-dose IVIG
17. However, consi-
dering the general conversion of cytokine profiles from 
Th2 to Th1
18 in late-stage AD, other mechanisms, such as 
recirculation of skin homing T cells and blockade of 
provoking antigens should also be considered.
In conclusion, we herein report a case in which IVIG 
monotherapy was very helpful in treating resistant AD in a 
child, without significant side effects. We also found that 
the remission period after treatments was longer than that 
of previous reports.
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